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Abstract 
Poor diet and sedentary lifestyle contribute to the development of metabolic syndrome (MetS); 
addressing both is crucial for its management. A diet featuring the Mediterranean dietary pattern 
or  low  glycemic  load  has  been  shown  to  prevent  and  ameliorate  MetS.  Plant  compounds, 
including soy protein and phytosterols, have been associated with reduced cardiovascular disease 
(CVD) risk. Recently, phytochemicals from hops and acacia were identified as lipogenic, anti-
inflammatory compounds that reduced serum insulin and glucose levels in animals. A 12-week, 
randomized  lifestyle  intervention  study  in  overweight  and  obese  women  with  LDL  ≥3.37 
mmol/L  (130  mg/dL)  compared  a  Mediterranean-style,  low-glycemic-load  diet  and 
soy/phytosterol-based medical food to an AHA low-fat diet. The modified Mediterranean diet 
with medical food was superior in reducing markers of MetS and CVD risk. A subsequent, 
randomized 12-week study in men and women with MetS and LDL ≥3.37 mmol/L (130 mg/dL) 
showed  that  supplementation  with  soy/phytosterol-based  medical  food  plus  phytochemicals 
enhanced the benefits of a Mediterranean-style low-glycemic-load diet and aerobic exercise. At 
the completion of the study, 43% of participants receiving medical food and phytochemicals 
exhibited net resolution of MetS compared with only 22% of those on diet and exercise alone. A Functional Foods in Health and Disease: 2011, 2: 38-49                                                       Page 39 of 49 
subanalysis of participants at high risk (MetS + LDL ≥4.14 mmol/L [160 mg/dL]) indicated 
minimal benefit from lifestyle change alone but marked benefits with the addition of medical 
food and phytochemicals. Case studies illustrate long-term benefits of this supplemented lifestyle 
change program. In conclusion, institution of a phytochemical-enhanced lifestyle intervention 
promises to be a clinically useful approach in MetS management. 
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Introduction 
Metabolic  Syndrome  (MetS)  is  a  cluster  of  interrelated  clinical  factors  including  insulin 
resistance,  dyslipidemia,  excess  body  weight,  and  elevated  blood  pressure.  Together,  these 
components increase an individual’s risk for several chronic diseases, including type 2 diabetes 
mellitus (T2DM) and cardiovascular disease (CVD). In 2004, it was estimated that 34% of adults 
in the US met criteria for MetS [1]. As the prevalence of MetS increases dramatically with age 
[1], and the mean age of the US population is rising, further increase in MetS incidence appears 
inevitable. Also, the associated healthcare costs  are projected to increase to unsustainable levels 
in 10-20 years, not only in the US, but in Europe and Asia as well [2, 3].   
An AHA and National Heart, Lung, and Blood Institute (NHLBI) scientific statement 
concluded “Lifestyle interventions are the initial therapies recommended for treatment of the 
metabolic syndrome. If lifestyle change is not sufficient, then drug therapies for abnormalities in 
the individual risk factors may be indicated” [4]. Lifestyle management consists of diet and 
exercise modification. The following research review demonstrates that lifestyle interventions 
with specific dietary changes and supplemental phytonutrients provide a feasible approach to 
managing patients with MetS. 
 
Nutritional Aspects 
Mediterranean-style  diet.  The  Mediterranean-style  diet  has  been  associated  with  a  reduced 
prevalence of MetS [5, 6]. The traditional Mediterranean diet is comprised of foods such as fruits 
and vegetables, olives and olive oil, fish and seafood, legumes and nuts, herbs and spices, whole 
grains, and moderate amounts of wine. Benefits of this food plan have been studied widely; for a 
detailed review, please see the companion paper in this supplement by Dr. Maria Luz Fernandez, 
“Metabolic Syndrome and the Mediterranean Diet”.   
 
Low-glyemic-load diet.  Glycemic load describes the quantity and the quality of carbohydrates in 
a food, taking into account the glycemic index. High glycemic index foods such as white bread, 
chips, and soft drinks may lead to fluctuations in serum glucose and insulin levels with resultant 
increase in appetite and subsequent weight gain [7, 8]. Increased dietary glycemic load has been 
associated with increased risk for CVD [9] and diabetes [10]. Modification of the Mediterranean Functional Foods in Health and Disease: 2011, 2: 38-49                                                       Page 40 of 49 
diet to exclude high glycemic index foods and to limit the use of alcohol and grains may provide 
even greater advantage for reducing risk factors for CVD and T2DM.   
 
Soy protein and plant sterols. Consumption of soy protein reduces serum cholesterol and risk for 
coronary heart disease [11-14]. Short-term soy consumption was found to reduce inflammatory 
markers and to increase plasma nitric oxide levels in postmenopausal women with MetS [15]. 
Plant sterols also have been shown to reduce cholesterol [11, 12] and heart disease risk [16]. In 
MetS patients, plant stanol esters were found to lower both triglycerides (TG) and non-HDL 
cholesterol [17]. In the  PROCAM study of men and women with  MetS, TG  were found to 
improve  in  relationship  to  the  sitosterol/cholesterol  ratio  (inversely  related).  Also,  the 
sitosterol/cholesterol  ratio  was  negatively  associated  with  BMI.  However,  the  ratio  was 
positively related to HDL cholesterol [18]. Plant sterols occur naturally in small amounts in 
foods such as vegetables, grains, nuts, and seeds, but most people do not consume enough from 
diet alone. Consumption of margarine products fortified with plant sterols reduces cholesterol 
[19]. According to the FDA [20], the amount of plant sterol esters required to reduce risk of 
CHD is at least 1.3 g/day. Thus, incorporation of soy protein and plant sterols into a lifestyle 
change program promises to be a valuable intervention for reducing heart disease risk. 
 
Targeted  phytochemicals.  Consumption  of  plant  foods  has  been  associated  with  reduced 
incidence of chronic diseases such as diabetes, CVD, and cancer. Phytochemicals from plants 
may  be  responsible  for  such  benefits,  possibly  due  to  their  effects  on  insulin  signaling  and 
inflammation. At the molecular level, chronic activation of protein kinase C (PKC) has been 
implicated in dysregulated insulin signaling [21]. Adipocytes release cytokines that induce an 
inflammatory response involving a host of intracellular protein kinases such as phosphoinositide 
3  kinase  (PI3K),  glycogen  synthase  kinase  3  (GSK-3),  and  PKC  [22-26].  Pharmaceutical 
research has targeted protein kinases, but has been hampered by adverse effects associated with 
these therapies. Little work has been done on development of protein kinase inhibitors from 
natural products for attenuating inflammation and regulating insulin signaling.   
Recently,  more  than  200  botanical  compounds  with  a  history  of  safe  use  have  been 
evaluated for their effects on lipogenesis and inflammation in 3T3-L1 adipocytes [27]. Lipogenic 
indices and adiponectin secretion, both indicators of insulin sensitivity, were compared in cells 
treated  with  either  natural  products  or  conventional  pharmaceuticals  such  as  metformin  and 
thiazolidinediones. These experiments revealed that rho iso-alpha acids (RIAA) extracted from 
hops (Humulus lupulus) and an extract from the bark and heartwood of Acacia nilotica, a tree 
native to Africa and India, were among the most potent of the tested compounds [27]. Acacia 
extract has a high concentration of proanthocyanidins (PAC) [27]. PAC also are found in tea, 
apple,  and  grape  seed,  and  have  been  shown  to  have  antioxidant,  anti-inflammatory,  and 
hypolipidemic properties (reviewed in [28]).   Functional Foods in Health and Disease: 2011, 2: 38-49                                                       Page 41 of 49 
In lipogenic assays, RIAA and PAC were more potent than metformin, troglitazone, or 
pioglitazone  [27].  Both  botanical  compounds  selectively  inhibited  protein  kinases  in  vitro.  
RIAA inhibited the activity of PI3K, GSK-3, and PKCβ in cell-free assays, and PAC inhibited 
GSK-3, IKKβ, and PKCβ [29]. When RIAA and PAC were combined in a defined ratio of 5:1 
(w/w), an enhanced effect was observed on inhibition of tumor necrosis factor (TNF)-α induced 
free fatty acid release from adipocytes, suggesting a reduction in lipolysis. In a db/db diabetic 
mouse model, RIAA and PAC administered at a ratio of 5:1 for 7 days synergistically decreased 
serum  glucose  and  insulin  levels  to  the  same  order  of  magnitude  as  were  observed  with 
metformin or rosiglitazone (unpublished data; personal communication with Dr. Matthew Tripp). 
These studies suggest that selectively acting natural compounds have the potential to be effective 
in the management of insulin resistance.  
 
Dietary interventions in clinical settings 
The  following  are  summaries  of  two  clinical  studies;  the  first  suggesting  that  a  soy  and 
phytosterol-containing medical food may be an appropriate clinical approach for individuals with 
MetS, and the second testing that hypothesis. In addition, two case reports of participants in the 
second study provide evidence supporting long-term benefits of a lifestyle management program 
that  includes  a  low-glycemic-load  Mediterranean-style  diet,  medical  food,  specific 
phytochemicals and aerobic exercise.  
 
Low-glycemic-load diet with medical food  
In a 12-week, randomized, controlled study, the AHA Step 1 low-fat diet (AHAD) [30] was 
compared  to  a  modified  Mediterranean-style,  low-glycemic-load  diet  (MED)  along  with  a 
medical food providing 30 g of soy protein and 4 g of phytosterols per day [31]. CVD risk 
factors were measured in overweight or obese postmenopausal women with serum LDL ≥3.37 
mmol/L (130 mg/dL). Both study arms followed an individually-planned, hypocaloric diet and 
~150 min/week of aerobic exercise calculated to achieve a weight loss goal of about one pound 
per week [31].  
While all women lost weight and experienced reductions in blood pressure and TG after 
12 weeks, only those in the MED/medical food arm experienced significant reductions from 
baseline in total cholesterol and LDL, as well as increased HDL [31]. Elevated TG/HDL ratio is 
a marker for MetS [32]. Women in the MED/medical food arm had significantly lower TG/HDL 
ratios, with a mean reduction of 42% from baseline compared with 17% in the AHAD arm [31], 
suggesting that subjects with MetS would be good targets for MED/medical food intervention.    
However, this study did not address whether benefits were due to MED and/or the medical food.     
 
Phytochemicals as part of nutritional intervention 
Using a similar design to the previous study, a second randomized controlled trial was initiated 
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benefit of the MED [33]. Participants were overweight and obese men and women with MetS, 
diagnosed according to ATP III criteria, with elevated LDL ≥3.37 mmol/L [130 mg/dL]. Both 
arms in the study followed the same lifestyle program consisting of the MED without imposed 
caloric  restriction  and  participation  in  ~150  min/week  of  aerobic  exercise.  The  control  arm 
followed  the  lifestyle  change  program  only;  the  phytochemical-enriched  diet  (PED)  arm 
additionally received the soy/phytosterol medical food and a tableted nutraceutical combination 
of RIAA:PAC twice daily.   
Participants in both arms lost a similar amount of weight (approximately 13 pounds) over 
the 12-week study. Waist circumference, fasting serum insulin levels, LDL, total cholesterol, 
non-HDL cholesterol, the ratio of apolipoprotein B to apolipoprotein A1 (ApoB/ApoA1), and 
hemoglobin A1c (HbA1c) values were reduced significantly at 12 weeks in both arms. Those in 
the  PED  arm  experienced  greater  reductions  in  total  cholesterol,  TG/HDL,  and  non-HDL 
cholesterol, compared with controls. Reductions in LDL and VLDL particle number (by NMR) 
were seen only in the PED arm. Notably, 43% of participants in the PED arm experienced net 
resolution of MetS, compared with only 22% in the control arm [33]. 
Interestingly, cravings for fast food, sweets, carbohydrates, and fats decreased after 2 weeks in 
all participants, and remained low for the duration of the study [33]. Likewise, between-meal 
hunger was decreased at 8 and 12 weeks. However, between the evening meal and bedtime, 
hunger decreased only in the PED arm at 8 and 12 weeks. 
Both  elevated  LDL  and  MetS  are  major  independent  CVD  risk  factors  that  carry 
comparable relative risk [34]. When elevated LDL coexists with MetS,  the risk for CVD is 
magnified [35, 36]. ATP III guidelines define LDL ≥4.14 mmol/L (160 mg/dL) as high risk for 
cardiovascular  events  [37].  To  examine  the  benefit  of  nutritional  intervention  in  high  risk 
subjects, subgroup analysis of study participants with baseline LDL ≥4.14 mmol/L (160 mg/dL) 
was  performed  [38].  Participants  in  the  PED  arm  had  a  26.5%  reduction  in  LDL  levels, 
compared with a reduction of 10.9% in the diet and exercise only control arm. At 12 weeks, LDL 
levels  in  all  participants  in  the  PED  arm  were  below  the  high  risk  range,  compared  with 
approximately 40% in the control arm. Half of those in the PED arm had LDL <3.37 mmol/L 
(130 mg/dL), while everyone in the control arm had LDL ≥3.37 mmol/L (130 mg/dL). In tandem 
with  lowering  of  LDL,  greater  reductions  of  total  cholesterol,  non-HDL  cholesterol,  and 
ApoB/ApoA1 were observed in the PED compared with the control arm. Participants in the 
control arm had little improvement in CVD risk factors. In contrast, administration of soy and 
phytosterol-based medical food with RIAA/PAC led to a significantly greater improvement in 
multiple CVD risk factors. These results indicate that a lifestyle program alone is inadequate in 
these high risk individuals and underscore the beneficial effects of the myriad nutritional factors 
provided by the medical food and the RIAA/PAC nutraceutical.   
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Two study participants were followed after study conclusion, and  their case studies demonstrate 
long-term benefit. A 40 year-old male had gained 55 kg (121 lbs) over about 20 years since high 
school;  he  ate  a  standard  American  diet  and  was  not  physically  active.  He  was  randomly 
allocated  to  the  control  (MED)  arm,  receiving  instructions  to  eat  a  low-glycemic-load, 
Mediterrranean-style diet and initiate an aerobic exercise program. At the end of the 12-week 
study period, the patient lost 10.8 kg (24 lbs), and experienced improvements in blood pressure, 
cholesterol, LDL, TG, and TG/HDL (Table 1).  However, HDL remained low and the patient 
still met all 5 criteria for MetS. He was followed for individual case management (ICM) and 
began supplementation with the soy/phytosterol medical food and RIAA/PAC nutraceutical at 
the same dose given to participants in the intervention arm of the study. After 7 months on this 
supplementation regimen, the patient lost an additional 17.1 kg (38 lbs) and experienced marked 
improvements in practically every variable (Table 1). As a result, the patient no longer met the 
criteria for MetS. 
Another  study  participant,  an  obese,  73  year-old  female  with  a  history  of 
hypercholesterolemia  and  hypertriglyceridemia  experienced  a  significant  weight  gain 
postmenopausally.  Her weight  increased about  14 kg  (31 lbs)  between ages 50 and 63, and 
another 14 kg (31 lbs) over the 15 months prior to her first study visit. She normally ate a 
standard American diet without fast food and did not smoke nor drink. Her physical activity was 
limited due to knee osteoarthritis. She was randomized to the PED arm with soy/phytosterol 
medical food and RIAA/PAC nutraceutical, and lost 10.7 kg (24 lbs) over 12 weeks (Table 2). 
At study completion, she no longer met the criteria for MetS. She then became an ICM patient 
and  continued  to  receive  the  medical  food  and  nutraceutical.  Over  15  months,  she  lost  an 
additional 6.8 kg (15 lbs), for a total weight loss of 17.5 kg (39 lbs) (approximately 18% of 
initial body weight) over 18 months. The patient continued to exhibit net resolution of MetS with 
remarkable improvements in HDL, TG and TG/HDL (Table 2). These two case studies indicate 
that  MetS  can  be  reversed  and  improvement  sustained  with  lifestyle  modification  including 
nutritional  supplementation  with  soy/phytosterol  based  medical  food  and  RIAA/PAC 
nutraceutical. 
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Table 1.  Summary of Case Study 1.  A male participant in the control arm of the 12-week 
metabolic  syndrome  study  initiated  a  phytochemical-enriched  diet  intervention  after  study 
completion.  Table is original to this manuscript. 
 
  Study start  End of 12-week study  7 months post-study 
Weight (lb)  256.3  232.5  194.9 
Waist circumference (in)  50.0  47.5  40.5 
Blood  pressure   (mm 
Hg) 
128/93  120/89  124/79 
BMI (kg/m
2)  39.5  35.9  30.1 
Cholesterol (mg/dL)  257.1  208.1  174.9 
Triglycerides  (TG)  
(mg/dL) 
472.6  187.6  87.6 
HDL (mg/dL)  30.1  30.1  39.0 
LDL (mg/dL)  161.0  140.2  118.1 
TG/HDL  15.8  6.3  2.3 
Fasting insulin (µU/mL)  12.7  11.6  2.8 
Fasting glucose (mg/dL)  93.7  95.5  88.3 
Hemoglobin A1c (%)  5.9  5.7  5.5 
Apolipoprotein-A1 
(mg/dL) 
150  160  140 
Apolipoprotein-B 
(mg/dL) 
140  130  90 
Apo-B/Apo-A1  0.9  0.8  0.7 
LDL particles (nmol/L)  1308  1181  1144 
 
Conversion factors to SI units: lb to kg, ÷ 2.2; in to cm, x 2.54; mg/dL to mmol/L for total, HDL 
and LDL cholesterol, x 0.0259; µU/mL to pmol/L for insulin, x 7.175; mg/dL to mmol/L for 
glucose, x 0.0555; mg/dL to mmol/L for TG, x 0.0113; mg/dL to g/L for Apolipoprotein-A1, B, 
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Table  2.  Summary  of  Case  Study  2.    A  female  participant  was  randomized  to  the 
phytochemical-enriched diet arm for the 12-week metabolic syndrome study, and continued the 
intervention after study completion.  Table is original to this manuscript. 
 
  Study start 
End of 12-week 
study 
11 months post-
study 
14  months 
post-study 
15  months 
post-study 
Weight (lb)  220.9  197.3  180.4  185.5  182.4 
Waist circumference 
 (in) 
47.0  45.0  N/A  44.0  N/A 
Blood pressure  (mm  
Hg)  
140/77  114/72  130/79  144/82  120/79 
BMI (kg/m
2)  37.3  33.4  30.6  31.3  30.9 
Cholesterol (mg/dL)  235.1  191.1  208.9  230.9  N/A 
Triglycerides (TG) 
 (mg/dL) 
192.0  123.9  125.7  91.2  N/A 
HDL (mgl/dL)  35.9  40.9  51.0  66.0  N/A 
LDL (mg/dL)  161.0  125.1  132.8  147.1  N/A 
TG/HDL*  5.3  3.0  2.5  1.4  N/A 
Fasting insulin 
 (µU/mL) 
18.2  17.2  11.1  N/A  N/A 
Fasting glucose  
(mg/dL) 
109.0  98.9  101.1  85.0  N/A 
Hemoglobin A1c (%)  5.7  5.7  5.6  N/A  N/A 
 
Conversion factors to SI units: lb to kg, ÷ 2.2; in to cm, x 2.54; mg/dL to mmol/L for total, HDL 
and LDL cholesterol, x 0.0259; µU/mL to pmol/L for insulin,  x 7.175; mg/dL to mmol/L for 
glucose, x 0.0555; mg/dL to mmol/L for TG, x 0.0113. 
 
Conclusions 
Diet and exercise are core ingredients of a healthy lifestyle. The studies reviewed indicate that 
lifestyle change including moderate exercise and a low-glycemic-load modified Mediterranean-
style diet was effective in the management of MetS. Addition of a soy/phytosterol containing 
medical  food  and  RIAA/PAC  nutraceutical  to  this  lifestyle  change  program  significantly 
enhanced  its  effectiveness  in  reducing  cardiometabolic  risk  factors  and  led  to  greater  net 
resolution of MetS. This effect occurred despite equal weight loss in both study arms. Further, 
patients at high CVD risk with both MetS and LDL ≥4.14mmol/L (160 mg/dL) experienced Functional Foods in Health and Disease: 2011, 2: 38-49                                                       Page 46 of 49 
greater benefit with addition of the medical food and nutraceutical. Case studies demonstrated 
prolonged improvement. Lifestyle intervention with targeted phytochemicals provides a rational 
clinical approach to the management of MetS. 
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